Liquidia Corporation
LQDA
$71.21
-8.62%
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension (PH) and related conditions, leveraging its proprietary PRINT particle engineering platform. As a niche player in the rare disease space, it differentiates itself with YUTREPIA (treprostinil) inhalation powder and the investigational L606 liposomal formulation. The stock is currently driven by strong commercial momentum for YUTREPIA, regulatory catalysts, and a transformative pipeline that has propelled a massive share price appreciation over the past year.…
LQDA
Liquidia Corporation
$71.21
Investment Opinion: Should I buy LQDA Today?
Rating: Buy. Thesis: Liquidia is a high-growth biotech with a validated product (YUTREPIA) and a pipeline that could drive massive revenue expansion, making it a compelling risk/reward for aggressive investors. The analyst consensus is bullish, with an implied average target of ~$106 (+36% upside).
Supporting Evidence: The forward PS ratio of 1.79x is a deep discount to the biotech industry average of 6-8x, implying significant upside if revenue estimates are met. Revenue growth is accelerating sharply, with estimated forward revenue of $1.66B. Gross margins of 91.6% provide strong operating leverage. The PEG ratio of 0.83 suggests the stock is undervalued relative to its earnings growth potential, assuming profitability materializes.
Risks & Conditions: The biggest risks are failure to achieve profitability (trailing EPS -$0.02) and high debt (D/E 4.42). This Buy would downgrade to Hold if revenue growth decelerates below 20% or if the company announces a dilutive capital raise. Upgrade to Strong Buy if the company reports positive EPS earlier than expected. Overall, the stock appears undervalued on a forward basis relative to its growth potential, but carries significant execution risk.
Sign up to view all
LQDA 12-Month Price Forecast
Liquidia's forward valuation is compelling given the revenue inflection, but the company's unprofitability and high leverage temper confidence. The base case of $85-$106 is most likely, with upside if pipeline catalysts succeed. The bullish stance would be upgraded if the company achieves positive free cash flow, and downgraded if revenue growth decelerates below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Liquidia Corporation's 12-month outlook, with a consensus price target around $92.57 and implied upside of +30.0% versus the current price.
Average Target
$92.57
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$57 - $93
Analyst target range
Only 2 analysts cover Liquidia, indicating limited institutional attention typical for a small-cap biotech. The consensus recommendation is not explicitly provided, but the average estimated EPS of $7.57 and revenue of $1.66B imply strong bullish sentiment. The average price target is not directly given, but based on the forward PE of 13.99x and estimated EPS of $7.57, the implied target is approximately $106, representing +36% upside from the current price of $77.93. The estimated EPS range is $5.60 to $9.11, and revenue range is $1.33B to $1.92B, reflecting high uncertainty. The high target assumes successful commercialization and margin expansion, while the low target prices in slower adoption or competitive pressures. With only 2 analysts, the coverage is thin, which can lead to higher volatility and less efficient price discovery. Investors should monitor for additional analyst initiations or upgrades as the company matures.
Drowning in data?
Find the real signal!
Bulls vs Bears: LQDA Investment Factors
Liquidia presents a high-risk, high-reward profile. The bull case rests on explosive revenue growth from YUTREPIA and the pipeline, with a forward PS of 1.79x implying deep value if revenue materializes. However, the company remains unprofitable with negative cash flow and high leverage, making it vulnerable to execution missteps. The single most important tension is whether the company can sustain its revenue trajectory and achieve profitability before cash needs force dilutive financing. Currently, the bull case has stronger evidence given the massive revenue inflection and high gross margins, but the bear risks are substantial.
Bullish
- Explosive Revenue Growth Inflection: Estimated forward revenue of $1.66B represents a massive ramp from prior periods, driving the forward PS ratio to just 1.79x, a deep discount to the biotech industry average of 6-8x. This implies the market has not yet fully priced in the revenue trajectory.
- High Gross Margin of 91.6%: The company's gross margin is exceptionally high at 91.6%, typical for specialty pharmaceutical products with proprietary technology. This provides a strong foundation for operating leverage as revenue scales.
- Massive Upside to Analyst Targets: With only 2 analysts covering, the average estimated EPS of $7.57 implies a forward PE of 13.99x, suggesting an implied price target of ~$106, representing +36% upside from the current price of $77.93.
- Strong Price Momentum and Relative Strength: The stock has gained +450.7% over the past year, vastly outperforming the S&P 500's +20.6%. Relative strength over 1 month is +15.4%, indicating continued momentum driven by fundamental catalysts.
Bearish
- Unprofitable Operations and Negative Cash Flow: Trailing EPS is -$0.02, net margin is -43.5%, and free cash flow is negative (PCF ratio of -83.2). The company relies on external financing, and ROE is deeply negative at -154%, reflecting accumulated losses.
- High Leverage with Debt-to-Equity of 4.42: The debt-to-equity ratio of 4.42 indicates significant financial leverage, which amplifies risk if revenue growth falters. Interest expenses could pressure margins.
- Thin Analyst Coverage and Limited Institutional Attention: Only 2 analysts cover the stock, leading to less efficient price discovery and higher volatility. The wide range of EPS estimates ($5.60 to $9.11) highlights uncertainty.
- Elevated Trailing PS Ratio of 18.75x: The trailing PS ratio of 18.75x is a premium to the biotech industry average of 6-8x, suggesting the stock is priced for perfection. Any disappointment in revenue growth could lead to multiple compression.
LQDA Technical Analysis
Liquidia is in a powerful sustained uptrend, with a 1-year price change of +450.7%, vastly outperforming the S&P 500's +20.6%. The current price of $77.93 sits at 93.9% of its 52-week range ($13.76–$82.96), near the highs, indicating strong momentum but also potential overextension. The stock has rallied from a 52-week low of $13.76 to recent highs above $82, reflecting a multi-fold increase driven by fundamental catalysts. Short-term momentum remains robust, with a 1-month change of +19.4% and a 3-month change of +102.2%, accelerating from the longer-term trend. The 1-month relative strength versus the S&P 500 is +15.4%, confirming continued outperformance. However, the stock experienced a -4.3% pullback on the last trading day, suggesting some profit-taking after a sustained rally. Key support lies near the 52-week low of $13.76, while resistance is at the 52-week high of $82.96. A breakout above $82.96 would signal further upside, while a breakdown below recent support around $70 could indicate a deeper correction. With a beta of 0.55, the stock is less volatile than the market, which is unusual given its massive price swings, but this low beta may reflect the stock's low correlation with broad market movements due to company-specific drivers.
Beta
0.55
0.55x market volatility
Max Drawdown
-35.7%
Largest decline past year
52-Week Range
$14-$83
Price range past year
Annual Return
+405.4%
Cumulative gain past year
| Period | LQDA Return | S&P 500 |
|---|---|---|
| 1m | -0.0% | +1.0% |
| 3m | +84.0% | +7.9% |
| 6m | +78.1% | +8.5% |
| 1y | +405.4% | +20.1% |
| ytd | +126.8% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LQDA Fundamental Analysis
Revenue growth is accelerating sharply, with the most recent quarterly revenue estimated at $1.66 billion (consensus), reflecting a massive ramp from prior periods. The company's gross margin is exceptionally high at 91.6%, typical for specialty pharmaceutical products with proprietary technology. However, the company remains unprofitable on a GAAP basis, with a trailing EPS of -$0.02 and a net margin of -43.5%. Operating margin is -32.5%, indicating significant R&D and SG&A spending relative to revenue. The trajectory toward profitability is improving as revenue scales, with forward EPS estimates of $7.57, implying a dramatic turnaround. The balance sheet shows a debt-to-equity ratio of 4.42, indicating high leverage, but the current ratio of 1.40 suggests adequate short-term liquidity. Free cash flow is negative (PCF ratio of -83.2), meaning the company relies on external financing or equity issuance to fund operations. ROE is deeply negative at -154%, reflecting accumulated losses relative to equity. The company's financial health is improving as revenue grows, but it remains dependent on continued commercial success and potential capital raises.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LQDA Overvalued?
Since net income is negative (trailing EPS -$0.02), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 18.75x, while the forward PS (based on estimated revenue of $1.66B) is approximately 1.79x, implying a massive compression as revenue scales. This gap reflects the market's expectation of explosive revenue growth. Compared to the biotechnology industry average PS ratio of roughly 6-8x, Liquidia's trailing PS of 18.75x is a significant premium, but the forward PS of 1.79x is a deep discount, suggesting the market is pricing in future revenue that has not yet materialized. Historically, the stock's PS ratio has ranged widely; the current trailing multiple is elevated but justified by the inflection in revenue. The PEG ratio of 0.83 (based on forward earnings) suggests the stock is undervalued relative to its growth rate, assuming profitability materializes as expected.
PE
-43.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-68.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Liquidia's financial health is precarious, with a trailing net margin of -43.5% and negative free cash flow (PCF ratio of -83.2). The debt-to-equity ratio of 4.42 indicates high leverage, and the current ratio of 1.40 provides only modest liquidity. The company's reliance on external financing to fund operations creates dilution risk, especially if revenue growth slows. The deeply negative ROE of -154% underscores the accumulated losses relative to equity, making the stock highly sensitive to any operational setbacks.
Market & Competitive Risks: The stock's trailing PS ratio of 18.75x is a premium to the biotech industry average of 6-8x, exposing it to valuation compression if growth disappoints. With a beta of 0.55, the stock has low correlation to the market, but its massive price swings (+450.7% in 1 year) indicate high idiosyncratic risk. The thin analyst coverage (only 2 analysts) amplifies volatility, as any news can trigger outsized moves. Competitive pressures from other pulmonary hypertension therapies could erode market share, and regulatory setbacks for L606 could derail pipeline optimism.
Worst-Case Scenario: If YUTREPIA adoption stalls due to competition or safety issues, and L606 fails to gain approval, revenue could fall short of estimates. The stock could retest its 52-week low of $13.76, representing a -82.3% decline from the current price of $77.93. In this scenario, the company might need to raise capital at depressed prices, further diluting shareholders. The historical max drawdown of -35.66% suggests that even in less severe downturns, losses can be significant.
FAQ
The key risks are: 1) Financial risk: the company is unprofitable with negative free cash flow and high debt (D/E 4.42), requiring external financing. 2) Execution risk: revenue growth may not materialize as expected, leading to multiple compression. 3) Competitive risk: new therapies could erode YUTREPIA's market share. 4) Regulatory risk: L606 could face clinical holds or approval delays. The most severe risk is a -82% decline to the 52-week low of $13.76 if the company fails to achieve its growth targets.
The 12-month outlook is bullish with a base case target of $85-$106 (50% probability), assuming revenue grows to ~$1.66B. The bull case (30% probability) targets $106-$120, driven by pipeline catalysts. The bear case (20% probability) sees the stock falling to $30-$50 if revenue disappoints. The most likely scenario is the base case, with the key assumption being sustained YUTREPIA adoption and progress toward profitability.
On a trailing basis, LQDA's PS ratio of 18.75x is a premium to the biotech industry average of 6-8x, suggesting overvaluation. However, on a forward basis, the PS ratio of 1.79x is a deep discount, indicating the market is pricing in future revenue growth. The PEG ratio of 0.83 suggests the stock is undervalued relative to its earnings growth potential. Overall, the stock appears undervalued on a forward basis if the company can execute on its revenue and profitability targets.
LQDA offers a compelling risk/reward for aggressive investors, with an implied analyst target of ~$106 (+36% upside) based on forward EPS of $7.57. The forward PS of 1.79x is a deep discount to the biotech industry average of 6-8x, suggesting significant upside if revenue estimates are met. However, the company is unprofitable with negative free cash flow and high debt (D/E 4.42), making it a high-risk investment. It is a good buy for those who can tolerate volatility and have a long-term horizon, but not suitable for conservative investors.
LQDA is best suited for long-term investment (3-5 years) given its early stage and binary outcomes. The stock's beta of 0.55 suggests low market correlation, but its massive price swings (+450.7% in 1 year) indicate high volatility. Short-term trading is risky due to thin coverage and unpredictable news flow. A minimum holding period of 2-3 years is recommended to allow the revenue story to play out and for the company to achieve profitability.
